Core Viewpoint - The stock price of Reap Bio fell by 2.09% on November 3, with a trading volume of 140 million yuan and a market capitalization of 9.806 billion yuan [1] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone. The company specializes in the research, production, and sales of veterinary biological products, chemical drugs, biological agents, traditional veterinary medicine, natural plant medicines, premixed feeds, feed additives, and veterinary raw materials [2] - The main business revenue composition is 77.95% from animal protection and 22.05% from the pet supply chain [2] - As of October 20, 2023, the number of shareholders is 25,000, with an average of 13,398 circulating shares per person [2] Financial Performance - For the period from January to September 2025, Reap Bio achieved a revenue of 2.544 billion yuan, representing a year-on-year growth of 45.66%. The net profit attributable to the parent company was 362 million yuan, with a year-on-year increase of 48.04% [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3] Shareholding Structure - As of September 30, 2025, the sixth largest circulating shareholder is the Guotai Zhongzheng Livestock Breeding ETF, holding 6.3383 million shares, an increase of 2.3571 million shares from the previous period. The Hong Kong Central Clearing Limited is the tenth largest shareholder, holding 3.6017 million shares, a decrease of 2.9711 million shares from the previous period [3]

Core Viewpoint - The stock price of Reap Bio fell by 2.00% on September 22, 2023, with a current price of 21.51 CNY per share and a market capitalization of 9.997 billion CNY [1] Group 1: Stock Performance - Reap Bio's stock has increased by 18.99% year-to-date, but has decreased by 2.14% in the last five trading days and 8.39% over the last 20 days [2] - The stock has shown a 10.76% increase over the past 60 days [2] Group 2: Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2] - The company's main business revenue composition is 77.95% from animal health and 22.05% from the pet supply chain [2] - Reap Bio is classified under the agricultural and animal health industry, with concepts including avian influenza drugs, pet economy, raw materials, synthetic biology, and investments in the New Third Board [2] Group 3: Financial Performance - For the first half of 2025, Reap Bio achieved a revenue of 1.708 billion CNY, representing a year-on-year growth of 55.37%, and a net profit attributable to the parent company of 257 million CNY, up 61.19% year-on-year [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion CNY in dividends, with 462 million CNY distributed over the last three years [3] Group 4: Shareholder Information - As of June 30, 2025, Reap Bio had 26,000 shareholders, with an average of 12,883 circulating shares per person [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3]

Core Viewpoint - Reap Bio has shown a mixed performance in stock price, with a year-to-date increase of 20.43% but a recent decline of 2.11% over the last five trading days [2] Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2] - The company's main revenue sources are: poultry biological products (35.04%), formulations and raw materials (33.24%), pet supply chain (20.63%), livestock biological products (6.86%), and others [2] Financial Performance - For the first half of 2025, Reap Bio achieved a revenue of 1.708 billion yuan, representing a year-on-year growth of 55.37%, and a net profit attributable to shareholders of 257 million yuan, up 61.19% [2] - Since its A-share listing, the company has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan in the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders stood at 27,000, with an average of 12,406 circulating shares per person [2] - Major shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3]

Core Viewpoint - The stock of Reap Bio has experienced fluctuations, with a recent decline in price and significant trading activity, indicating potential investor concerns and market dynamics [1][2]. Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2]. - The company's main revenue sources include poultry biological products (35.04%), formulations and raw materials (33.24%), pet supply chain (20.63%), livestock biological products (6.86%), and others [2]. Financial Performance - For the first half of 2025, Reap Bio reported a revenue of 1.708 billion yuan, representing a year-on-year growth of 55.37%, and a net profit attributable to shareholders of 257 million yuan, up 61.19% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3].

Company Overview - Reap Bio is located in Tianjin Free Trade Zone and was established on August 2, 2001, with its listing date on September 17, 2010 [1] - The company specializes in veterinary biological products (animal vaccines) and chemical pharmaceuticals [1] Stock Performance - As of August 22, Reap Bio's stock price decreased by 2.01%, trading at 22.93 CNY per share, with a total market capitalization of 10.657 billion CNY [1] - Year-to-date, the stock price has increased by 26.85%, with a 0.66% rise over the last five trading days, a 4.61% increase over the last 20 days, and a 7.02% decline over the last 60 days [1] Financial Performance - For the period from January to March 2025, Reap Bio reported a revenue of 822 million CNY, representing a year-on-year growth of 54.09% [2] - The company has distributed a total of 1.371 billion CNY in dividends since its A-share listing, with 462 million CNY distributed over the last three years [2] Shareholder Information - As of August 8, the number of shareholders for Reap Bio was 27,000, with an average of 12,406 circulating shares per shareholder [2] - As of March 31, 2025, the fifth largest circulating shareholder is Harvest Agricultural Industry Stock A, holding 6.3889 million shares, an increase of 696,900 shares from the previous period [2] Market Activity - On August 22, the net outflow of main funds was 7.9021 million CNY, with large orders accounting for 15.94% of purchases and 21% of sales [1]